Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:28 PM
Ignite Modification Date:
2025-12-24 @ 9:28 PM
NCT ID:
NCT04130932
Eligibility Criteria:
Inclusion Criteria:
* Ability to provide informed consent
* Must be adults between the ages of 18 and 60
* Ability to relocate to the Well Living Lab for 9 consecutive weeks
* Full-time Mayo Clinic employees (35+ hours per week)
* Report working a sedentary job (e.g., sit for \>= 50% of their work time).
* Have a working mobile phone that can receive text messages
* Must be present for 80% of the study (minimum of 4 days per week)
Exclusion Criteria:
* Individuals who are shift-workers
* Individuals diagnosed with vascular diseases (i.e., Raynaud's disease, peripheral artery disease, etc.)
* Individuals with diagnosed neurological and psychiatric disorders that may have physical limitations
* Drug (illegal or prescription narcotic), nicotine, or alcohol dependency
* Women who are lactating, pregnant or intend to become pregnant during the duration of the study
* Individuals who are taking medications (either prescribed or over-the-counter) which may affect comfort levels (e.g., opiate based medications)
* Working in occupation requiring standing/stepping \>50% of work time
* Report \< 1 year at current job
* Hospitalization from either a physical or mental disorder in the past six months
* History of cardiovascular, pulmonary, metabolic, neurological, or orthopedic limitations that would prohibit occupational physical activity (e.g., standing, stepping, etc.)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
60 Years
Study:
NCT04130932
Study Brief:
Protocol Section:
NCT04130932